Allogene Therapeutics, Inc. (ALLO)
1.325
0.00 (0.00%)
USD |
NASDAQ |
Oct 21, 16:00
1.325
0.00 (0.00%)
After-Hours: 20:00
Allogene Therapeutics Net Income (Quarterly) : -42.68M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -42.68M |
| March 31, 2026 | -42.61M |
| December 31, 2025 | -38.81M |
| September 30, 2025 | -41.40M |
| June 30, 2025 | -50.94M |
| March 31, 2025 | -59.73M |
| December 31, 2024 | -59.94M |
| September 30, 2024 | -66.29M |
| June 30, 2024 | -66.36M |
| March 31, 2024 | -65.00M |
| December 31, 2023 | -85.78M |
| September 30, 2023 | -62.29M |
| June 30, 2023 | -79.23M |
| March 31, 2023 | -99.97M |
| December 31, 2022 | -94.85M |
| September 30, 2022 | -83.15M |
| June 30, 2022 | -74.79M |
| March 31, 2022 | -79.85M |
| Date | Value |
|---|---|
| December 31, 2021 | -74.87M |
| September 30, 2021 | -78.19M |
| June 30, 2021 | -70.94M |
| March 31, 2021 | -33.02M |
| December 31, 2020 | -68.57M |
| September 30, 2020 | -66.20M |
| June 30, 2020 | -60.97M |
| March 31, 2020 | -54.48M |
| December 31, 2019 | -61.03M |
| September 30, 2019 | -50.74M |
| June 30, 2019 | -41.24M |
| March 31, 2019 | -31.59M |
| December 31, 2018 | -30.51M |
| September 30, 2018 | -43.50M |
| June 30, 2018 | -137.50M |
| March 31, 2018 | -2.597M |
| December 31, 2017 | -0.002M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
| Anixa Biosciences, Inc. | -2.625M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 4.64M |
| Total Expenses (Quarterly) | 47.32M |
| EPS Diluted (Quarterly) | -0.1297 |
| Enterprise Value | 205.71M |
| Gross Profit Margin (Quarterly) | 43.00% |
| Profit Margin (Quarterly) | -919.8% |
| Earnings Yield | -50.20% |
| Normalized Earnings Yield | -50.20 |